Articles tagged with: Education

27
June
2017

Urologist in Adelaide - Prostate Biopsy

Urologist in Adelaide - Prostate Biopsy

Urologist in Adelaide, Nick Brook using the Mona Lisa Biobot


Robotic prostate biopsy

In January 2017, Nick Brook organised for a 6 month free trial of the Biobot robotic biopsy system at the Royal Adelaide Hospital. This is the first such system in South Australia, and was only the third in use in Australia.

The system uses a patient's MRI scan and fuses this with a real-time ultrasound of the prostate to enable targeting of suspicious areas in the prostate.


Increased accuracy of diagnosis leads to increased confidence that the correct treatment can be chosen.

Software controls the robotic arm, to ensure that the needles are placed in the correct position for biopsy

The Advertiser story on the introduction of the Biobot to South Australia by Nick Brook can be found here

Categories: Updates

15
June
2017

Nick Brook Urology Website online again

Nick Brook Urology Website online again

Adelaide Urologist Associate Professor Nick Brook has re-launched his urology practice website.


The website is relaunched

This was the most visited urology website in Adelaide, and has returned with updated patient information on urology conditions and procedures.

It highlights treatment options for prostate cancer, kidney stones, bladder stones, kidney cancer, vasectomy, vasectomy reversal and many others.


Optimised for mobile, tablet and desktop

You can view the website on your chosen device, for all the information you need on urology problems.


Categories: Updates

03
January
2015

Hamlin Fistula Ethiopia break the $6M mark

Hamlin Fistula Ethiopia break the $6M mark

Towards the end of 2014, Hamlin Fistula Ethiopia smashed the $6M mark in income since the charity in Australia was created just over two years ago.


Dr. Hamlin and the whole team at Hamlin Fistula Ethiopia in Australia and Ethiopia have had a huge impact on the lives of the women with obstetric fistula they treat and train.


Our practice will be supporting the work of this charity in 2015 and encourage you to read about the amazing work they do.

Please read more about the work of Hamlin Fistula Ethiopia and stay up to date with latest news from Nick Brook Urology, as we support this work throughout 2015.


Follow this link to a short youtube video

And please pass on the links to Hamlin Fistula Ethiopia, via word of mouth, email and social media - the work they do is so important. You can follow Hamlin Fistula on Twitter.


Categories: Updates

29
November
2014

Nick Brook Urology Moving to New Location

Nick Brook Urology Moving to New Location

The North Adelaide practice has grown rapidly, and we are moving the rooms to a new location. We will be moving on the 16th December, and will be sending details through the post to all our patients.


Where are we moving to?

The new address for the the practice is Calvary North Adelaide Hospital (Ground Floor), 89 Strangways Terrace, North Adelaide SA 5006. The new telephone number is 08 8267 1424

The email address and website will stay the same; email: This email address is being protected from spambots. You need JavaScript enabled to view it., website www.nickbrookurology.com


Why are we moving?

The practice has grown significantly and the new location at Calvary North Adelaide Hospital has more space to allow for staff expansion, but importantly will offer many benefits for patients:

  • Located in a major private hospital
  • Easy ground floor access for patients, with 2 hour parking
  • Direct access for patients to radiology and pathology - located on the same corridor
  • On-site access for patients to Continence Nurse expertise
  • Immediate booking of procedures from clinic
  • In-patients have access to our office facilities and support

When are we moving?

16th December 2014. If you have an appointment prior to this date, then please come to the old 175 Ward Street address. After the 16th December, all consulting will be at Calvary North Adelaide Hospital. We are on the ground floor. Just ask at reception, and they will point you to the new rooms.


What if I need further information?

We are writing to all our patients and their GPs to let them know about the move, with all the details of the new location. If you have any questions, Jane or Heather will be pleased to help. Before 16th December, call them on 8267 2200, after that date, call them on 82671424. We apologise for any inconvenience, and we are confident that you will find the new location is able to meet your expectations as a customer of the practice.


Categories: Updates

30
November
2014

Enzalutamide available on the PBS

Enzalutamide available on the PBS

From 1 December 2014, a new drug for advanced prostate cancer will be available and listed on the PBS. Enzalutamide is an oral drug used for advanced prostate cancer (metastatic castration resistant prostate cancer). It works by inhibiting binding of androgens (such as testosterone) to the androgen receptor (AR), as well as inhibiting the AR from entering the cell nucleus and from binding to DNA. It has had encouraging results in clinical trials.


What are the PBS criteria for enzalutamide?

The treatment cannot be used in combination with chemotherapy (docetaxel in the common chemotherapy agent used in advanced prostate cancer)

AND

The patient must have failed treatment with docetaxel due to resistance (this generally means progression of disease or non-response to docetaxel) or intolerance

OR

The patient must be unsuitable for docetaxel treatment on the basis of predicted intolerance to docetaxel

AND

Patient must have a World Health Organisation Performance Status of 2 or less (this means good performance)

AND

The patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug

AND

The patient must not have received prior treatment with abiraterone

OR

Patient must have developed intolerance to abiraterone of a severity necessitating permanent withdrawal of abiraterone.

Categories: Updates, Prostate Cancer

30
November
2014

Abiraterone PBS listing changed from 1st December 2014

Abiraterone PBS listing changed from 1st December 2014

From December 2014 , the PBS criteria for abiraterone acetate changed, meaning that patients deemed unsuitable for chemotherapy with doxetaxel can be prescribed PBS-subsidised abiraterone.


What is abiraterone?

Abiraterone is an oral drug for metastatic prostate cancer that is castration resistant (meaning the cancer that is no longer sensitive to other forms of testosterone suppression). It works by inhibiting an enzyme involved in the production of androgens (testosterone is one of the body’s androgens).


What are the new amended PBS criteria?

Treatment must be in combination with a steroid (prednisolone)

Treatment can’t be given in combination with chemotherapy

Patients must have failed treatment with docetaxel because of resistance or intolerance, or be considered unsuitable for docetaxel chemotherapy because of proven or predicted intolerance to the chemotherapy.

Patients must have a good performance status (WHO status of 2 or less)

If progressive disease develops whilst on abiraterone, PBS-subsidised treatment with abiraterone cannot continue.

Patients cannot have previously received treatment with enzalutamide, or they must have developed intolerance to enzalutamide, which was bad enough to require that enzalutamide was stopped.

Categories: Updates, Prostate Cancer

Affiliations

Urology Affiliations

Latest Tweets

Contact Us

  • Nick Brook Urology
    Calvary North Adelaide Hospital
    89 Strangways Tce,
    North Adelaide,
    Adelaide SA 5006
  • 08 8267 1424
  • 08 8267 1370